Women with myasthenia gravis (MG) have more severe disease and worse quality of life than men, according to a study in Germany, which also found overweight patients had poorer quality of life too. The delay in being diagnosed was also longer for women than for men, which may result…
News
People living with generalized myasthenia gravis (gMG) in the U.S. who experience certain barriers to healthcare reported major economic concerns in a new patient survey. These patients highlighted issues related to managing funds for emergency care, loss of income, and other non-medical expenses as contributing to a greater economic…
The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under the brand name Zilbrysq, for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). With this approval, Zilbrysq has now become the…
Measuring how much immunoglobulin G (IgG) antibody levels drop after plasmapheresis, a blood-cleansing treatment for myasthenia gravis (MG), may help in determining the disease’s likely course, at least in the short term, a small study suggests. Changes in this potential biomarker that signal improvement also could help in…
Daily treatment with zilucoplan was tied to meaningful reductions in symptom severity among the subgroup of Japanese generalized myasthenia gravis (gMG) patients who participated in the Phase 3 RAISE clinical trial, according to new subgroup analyses. The data add to accumulating trial evidence that the UCB therapy…
About two years treatment with the immunosuppressant tacrolimus safely and effectively eases symptoms in children and adolescents with myasthenia gravis (MG) while cutting down the need for oral prednisone, according to a small study in China. Corticosteroids like prednisone, often used when other medications fail to control…
A treatment based on GRO Biosciences‘ ProGly program — which uses specially designed proteins to regulate the immune system — substantially reduced disease activity in an animal model of myasthenia gravis (MG), according to new data presented by the company. “We are greatly encouraged by the results of…
UCB’s zilucoplan and Rystiggo (rozanolixizumab) both were approved in Japan to treat adults with generalized myasthenia gravis (gMG) who lack an adequate response to steroids or other immunosuppressive treatments. “With the approval in Japan of zilucoplan and [Rystiggo], we are very proud and excited to expand our…
Health Canada has approved Vyvgart (efgartigimod alfa-fcab) to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common target of MG-causing antibodies. The approval is based on positive data from the Phase 3 ADAPT clinical trial (NCT03669588),…
A more severe disease course was seen among pediatric myasthenia gravis (MG) patients with antibodies against acetylcholine receptors (AChRs) who also have antibodies against ryanodine receptors (RyR) and the titin protein, according to a new study. These children had a higher likelihood of having generalized MG (gMG) and…
Recent Posts
- Does myasthenia gravis really have that much power over me?
- Recovery after MG flares takes many months, even with newer meds: Study
- Severe MG, high corticosteroid dose tied to worse psychological distress
- I’m limiting my news consumption to better manage my health with MG
- New Phase 3 study results support Vyvgart Hytrulo in ocular MG